Repository

• Home
• Repository
• Publications

Publications

Gut-to-Bile transfer of microbially amidated minor bile acids in patients with hepatopancreatobiliary disorders Temprano AG, Romero MR, Ghallab A, Llera L, Macias RIR, van Eijk HM, Rullán M, Urman J, Ay Ü, Lenicek M, Hengstler JG, Neumann UP, Berasain C, Avila MA, Olde Damink SWM, Monte MJ, Marin JJG, Schaap FG. Hepatology. 2025 Jun 23. doi: 10.1097/HEP.0000000000001441 2025  Result from   OA Funded by

Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real-life worldwide population Prinzi FL, Salani F, Camera S, Rizzato MD, Saborowski A, Antonuzzo L, Rossari F, Satake T, Peeters F, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Gallio C, Tamberi S, Finkelmeier F, Giordano G, Chiara P, Chon HJ, Braconi C, Qaisar A, Pastorino A, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Couto N, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Alvim CM, Roque R, Polito MG, Di Giacomo E, Farinea G, Bartalini L, Grelli G, De Rosa A, Lavacchi D, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Tesini G, Boccaccino A, Himmelsbach V, Landriscina M, Djaballah SA, Bekaii-Saab T, Fornaro L, Masi G, Vogel A, Lonardi S, Rimini M, Rimassa L, Casadei-Gardini A. Int J Cancer . 2025 Nov 15;157(10):2092-2102. doi: 10.1002/ijc.70009 2025  Result from

The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide population Rimini M, Fornaro L, Lo Prinzi F, Rizzato MD, Saborowski A, Antonuzzo L, Rossari F, Satake T, Peeters F, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Nichetti F, Jae Chon H, Braconi C, Qaisar A, Pirrone C, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Corallo S, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Alvim CM, Roque R, Farinea G, Salani F, De Rosa A, Lavacchi D, Camera S, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Bekaii-Saab T, Esposito L, Boccaccino A, Himmelsbach V, Landriscina M, Djaballah SA, Zanuso V, Malapelle U, Pepe F, Masi G, Vogel A, Lonardi S, Rimassa L, Casadei-Gardini A. J Natl Cancer Inst . 2025 Oct 1;117(10):2029-2043. doi: 10.1093/jnci/djaf155 2025  Result from

Targeting EIF4A1 is effective against human intrahepatic cholangiocarcinoma Mi W, Cigliano A, Galleri G, Gigante I, Steinmann SM, Cibali E, Serra M, Pes GM, Schloesser D, Pizzuto E, Siegmund H, Fischer C, Saborowski A, Giannelli G, Evert M, Wilhelmus van der Laan LJ, Verstegen MMA, Calvisi DF JHEP Rep. 2025 Apr 3;7(7):101416. doi: 10.1016/j.jhepr.2025.101416 2025  Result from

From barriers to solutions: an expert-based algorithm for cholangiocarcinoma and other biliary tract cancers testing in the Era of precision oncology Stenzinger A, Normanno N, Lamarca A, Rimassa L, Bibeau F, Taniere P, Vogel A, Hollebecque A. Expert Rev Mol Diagn . 2025 Aug;25(8):495-508. doi: 10.1080/14737159.2025.2521538 2025  Result from